SC
ARQT icon

Stephens Consulting’s Arcutis Biotherapeutics ARQT Stock Holding History

Stephens Consulting’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$391 – 1255
2025
Q1 		$391 Buy
+25
New +$352 ﹤0.01% 1082

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Stephens Consulting's ARQT Position: Q2 2025 in Review

Stephens Consulting sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 25 shares — an estimated $391 sold.

Stephens Consulting first reported a position in ARQT in Q1 2025 and held it in 1 quarter. The position peaked at $391 in Q1 2025. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

  • Stephens Consulting reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 25 Arcutis Biotherapeutics shares in Q2 2025, an estimated $391.
  • Stephens Consulting first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Arcutis Biotherapeutics position peaked at $391 in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.